コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 se-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation.
2 velopment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
3 rapy to treat malignancies in the context of allogeneic hematopoietic stem cell transplantation.
4 , which include medical therapy, surgery, or allogeneic hematopoietic stem cell transplantation.
5 potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation.
6 ading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation.
7 nd were greater than 1 year from the time of allogeneic hematopoietic stem cell transplantation.
8 nic graft-versus-host disease (GVHD) follows allogeneic hematopoietic stem cell transplantation.
9 cute myelogenous leukemia and was undergoing allogeneic hematopoietic stem cell transplantation.
10 nd immune recovery, and one had a subsequent allogeneic hematopoietic stem cell transplantation.
11 han those in molecular remission, even after allogeneic hematopoietic stem cell transplantation.
12 t's response to therapy, and improvements in allogeneic hematopoietic stem cell transplantation.
13 se with limited myeloid reconstitution after allogeneic hematopoietic stem cell transplantation.
14 atients who survived more than 2 years after allogeneic hematopoietic stem cell transplantation.
15 ell repertoire, which would be of benefit in allogeneic hematopoietic stem cell transplantation.
16 used increasingly as an immunosuppressant in allogeneic hematopoietic stem cell transplantation.
17 associated with adverse clinical outcomes in allogeneic hematopoietic stem cell transplantation.
18 bloodstream infection in patients undergoing allogeneic hematopoietic stem cell transplantation.
19 s are the main goals of T-cell therapy after allogeneic hematopoietic stem cell transplantation.
20 mbotic microangiopathy that occurs following allogeneic hematopoietic stem cell transplantation.
21 a major cause of morbidity and mortality in allogeneic hematopoietic stem cell transplantation.
22 ents with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation.
23 host responses that influence the outcome of allogeneic hematopoietic stem cell transplantation.
24 n is a rare but fatal complication following allogeneic hematopoietic stem cell transplantation.
25 is presently no curative therapy other than allogeneic hematopoietic stem cell transplantation.
26 crimal gland graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
27 r cell leukemia is a rare complication after allogeneic hematopoietic stem cell transplantation.
28 ere examined in a mouse model of MHC-matched allogeneic hematopoietic stem cell transplantation.
29 able advances have been made in the field of allogeneic hematopoietic stem cell transplantation.
30 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.
31 s syndrome is a frequent condition following allogeneic hematopoietic stem cell transplantation.
32 n animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.
33 Only 7 patients underwent allogeneic hematopoietic stem cell transplantation.
34 with B-cell malignancies refractory to prior allogeneic hematopoietic stem cell transplantation.
35 t disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation.
36 y regulated post-transplantation immunity in allogeneic hematopoietic stem-cell transplantation.
37 sociated with survival after unrelated-donor allogeneic hematopoietic stem-cell transplantation.
38 rs for male recipients worsen the outcome of allogeneic hematopoietic stem-cell transplantation.
39 -versus-host disease (GVHD) to therapy after allogeneic hematopoietic stem-cell transplantation.
40 utations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.
41 onse to DBY in a recipient of sex mismatched allogeneic hematopoietic stem-cell transplantation.
42 e CD19 specific, for adoptive transfer after allogeneic hematopoietic stem-cell transplantation.
43 ents with multiple myeloma who relapse after allogeneic hematopoietic stem-cell transplantation.
44 function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation.
45 dition, the affected infant was treated with allogeneic hematopoietic stem-cell transplantation.
46 ading cause of later illness and death after allogeneic hematopoietic stem-cell transplantation.
48 osphorylase replacement has been achieved by allogeneic hematopoietic stem cell transplantation, a pr
49 ate of a subgroup of 9 patients who received allogeneic hematopoietic stem cell transplantation after
50 phase 2 clinical trial of reduced-intensity allogeneic hematopoietic stem cell transplantation (AHSC
51 auses significant morbidity and mortality in allogeneic hematopoietic stem cell transplantation (aHSC
52 244 samples from 26 pediatric recipients of allogeneic hematopoietic stem cell transplantation (AHSC
53 mune responses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSC
54 More than 25,000 allogeneic hematopoietic stem cell transplantations (all
55 e of adult intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo
56 Allogeneic hematopoietic stem cell transplantation (allo
57 Although allogeneic hematopoietic stem cell transplantation (allo
58 NX1/RUNX1T1 transcript levels could identify allogeneic hematopoietic stem cell transplantation (allo
59 In allogeneic hematopoietic stem cell transplantation (allo
60 rsus-host disease (GVHD) in a mouse model of allogeneic hematopoietic stem cell transplantation (allo
61 Patients undergoing allogeneic hematopoietic stem cell transplantation (allo
62 butes to the risk of severe infections after allogeneic hematopoietic stem cell transplantation (allo
63 The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (allo
64 donor vs host MHC on their development after allogeneic hematopoietic stem cell transplantation (allo
65 e is known of HEV infection in recipients of allogeneic hematopoietic stem cell transplantation (allo
66 llowing reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo
67 (GVHD) is still a leading complication after allogeneic hematopoietic stem cell transplantation (allo
68 ngiogenesis has not been investigated during allogeneic hematopoietic stem cell transplantation (allo
69 regs in healthy donors and in patients after allogeneic hematopoietic stem cell transplantation (allo
70 D) donor lymphocyte infusion (DLI) after TCD allogeneic hematopoietic stem cell transplantation (allo
71 Allogeneic hematopoietic stem cell transplantation (allo
72 ricted T cell receptor (TCR) diversity after allogeneic hematopoietic stem cell transplantation (allo
73 ded for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (allo
74 In allogeneic hematopoietic stem cell transplantation (allo
75 The clinical value of allogeneic hematopoietic stem cell transplantation (allo
76 gainst certain malignancies in recipients of allogeneic hematopoietic stem cell transplantation (allo
77 elapse-related morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo
78 OF REVIEW: Despite the curative potential of allogeneic hematopoietic stem cell transplantation (allo
79 Delays in immune recovery after allogeneic hematopoietic stem cell transplantation (allo
80 Bacteremia is a frequent complication of allogeneic hematopoietic stem cell transplantation (allo
81 The clinical goal of allogeneic hematopoietic stem cell transplantation (allo
82 is a frequent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo
83 s.-host disease (cGVHD) is a complication of allogeneic hematopoietic stem cell transplantation (allo
84 Whether CD20 influences outcomes after allogeneic hematopoietic stem cell transplantation (allo
85 Donor T cells contribute to the success of allogeneic hematopoietic stem cell transplantation (allo
86 myeloid leukemia (AML) patients treated with allogeneic hematopoietic stem cell transplantation (allo
87 herapeutic applications defining the role of allogeneic hematopoietic stem cell transplantation (allo
88 However, in allogeneic hematopoietic stem cell transplantation (allo
89 Prospective data on the value of allogeneic hematopoietic stem cell transplantation (allo
90 Allogeneic hematopoietic stem cell transplantation (allo
91 Much of the efficacy of allogeneic hematopoietic stem cell transplantation (allo
92 on alloreactive T cells in recipients of an allogeneic hematopoietic stem cell transplantation (allo
93 immunity, have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo
94 Allogeneic hematopoietic stem cell transplantation (allo
95 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo
96 ental graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo
97 ed by monocytes, it has been speculated that allogeneic hematopoietic stem cell transplantation (allo
98 y graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo
99 Reporting allogeneic hematopoietic stem cell transplantation (allo
100 elphia (Ph) chromosome to chemotherapy or to allogeneic hematopoietic stem-cell transplantation (allo
101 The effectiveness of allogeneic hematopoietic stem-cell transplantation (allo
102 kemia (GVL) because patients relapsing after allogeneic hematopoietic stem-cell transplantation (allo
103 s (EBV) serostatus on the overall outcome of allogeneic hematopoietic stem-cell transplantation (allo
104 lignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (allo
105 .4 days (interquartile range, 15.1-139 d) in allogeneic hematopoietic stem cell transplantation and 1
106 developed in 75 patients (15.6%) undergoing allogeneic hematopoietic stem cell transplantation and 5
107 sease (cGVHD) is a notorious complication of allogeneic hematopoietic stem cell transplantation and c
108 report that tumor-directed vaccination after allogeneic hematopoietic stem cell transplantation and d
109 promising treatment approaches that include allogeneic hematopoietic stem cell transplantation and i
110 th advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and m
111 e first lymphoid population recovering after allogeneic hematopoietic stem cell transplantation and p
112 mmunodeficiency (SCID) can be cured by using allogeneic hematopoietic stem cell transplantation, and
113 (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and
114 infection risk, (2) improving the outcome of allogeneic hematopoietic stem cell transplantation, and
115 disease (aGVHD) is the main complication of allogeneic hematopoietic stem cell transplantation, and
116 nce the most common indication for unrelated allogeneic hematopoietic stem cell transplantation but h
117 t disease (cGVHD) is a major complication of allogeneic hematopoietic stem cell transplantation but t
119 Allogeneic hematopoietic stem cell transplantation combi
120 Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation conti
121 the fecal microbiota of patients undergoing allogeneic hematopoietic stem cell transplantation demon
122 rvival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do no
123 linical experience with adoptive transfer of allogeneic hematopoietic stem cell transplantation donor
124 D14(+)CD16(+) monocytes can be isolated from allogeneic hematopoietic stem cell transplantation donor
125 -) and CD14(+)CD16(+) monocytes from healthy allogeneic hematopoietic stem cell transplantation donor
126 e on their nationwide retrospective study of allogeneic hematopoietic stem cell transplantation for a
127 s (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for m
128 t molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for M
129 ent with acute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from
130 ioimmunotherapy, therapeutic vaccination and allogeneic hematopoietic stem cell transplantation, have
131 press graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HCT
132 st disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HCT)
133 eration of immunity is a major problem after allogeneic hematopoietic stem cell transplantation (HCT)
134 etrimental late pulmonary complication after allogeneic hematopoietic stem cell transplantation (HCT)
137 tion in CMV-positive recipients (R(+)) after allogeneic hematopoietic stem cell transplantation (HCT)
138 Despite improvements in the practice of allogeneic hematopoietic stem cell transplantation (HCT)
139 Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT)
140 potentially life-threatening complication of allogeneic hematopoietic stem cell transplantation (HCT)
141 r cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HCT)
142 tive care, both long-term survival following allogeneic hematopoietic stem cell transplantations (HSC
143 e a frequent and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT
144 ronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic stem cell transplantation (HSCT
145 Allogeneic hematopoietic stem cell transplantation (HSCT
146 Allogeneic hematopoietic stem cell transplantation (HSCT
147 MVR) is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT
148 the reduction in HIV-1 reservoirs seen after allogeneic hematopoietic stem cell transplantation (HSCT
149 To accurately define the outcome after allogeneic hematopoietic stem cell transplantation (HSCT
150 ess in 48 patients who were >1 year out from allogeneic hematopoietic stem cell transplantation (HSCT
151 th either RAG or ARTEMIS mutations following allogeneic hematopoietic stem cell transplantation (HSCT
152 Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT
153 Allogeneic hematopoietic stem cell transplantation (HSCT
154 Allogeneic hematopoietic stem cell transplantation (HSCT
155 ith myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (HSCT
156 Allogeneic hematopoietic stem cell transplantation (HSCT
157 After allogeneic hematopoietic stem cell transplantation (HSCT
158 Allogeneic hematopoietic stem cell transplantation (HSCT
159 CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT
160 xamines reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT
161 or (GVT) effects remains a paramount goal in allogeneic hematopoietic stem cell transplantation (HSCT
162 Although allogeneic hematopoietic stem cell transplantation (HSCT
163 Allogeneic hematopoietic stem cell transplantation (HSCT
164 The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT
165 llogeneic T cell response in hosts receiving allogeneic hematopoietic stem cell transplantation (HSCT
166 elapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT
167 lities in acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT
168 e antigen (anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT
169 ion is a potentially serious complication of allogeneic hematopoietic stem cell transplantation (HSCT
170 management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT
171 Their role in human conventional allogeneic hematopoietic stem cell transplantation (HSCT
172 ediction of nonrelapse mortality (NRM) after allogeneic hematopoietic stem cell transplantation (HSCT
173 (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT
174 ycetes have a poor outcome, in particular in allogeneic hematopoietic stem cell transplantation (HSCT
175 d graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT
176 t important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT
177 Allogeneic hematopoietic stem cell transplantation (HSCT
178 ith measurable changes in Treg subsets after allogeneic hematopoietic stem cell transplantation (HSCT
179 Allogeneic hematopoietic stem cell transplantation (HSCT
180 ral infections are major complications after allogeneic hematopoietic stem cell transplantation (HSCT
181 idity and mortality in patients treated with allogeneic hematopoietic stem cell transplantation (HSCT
182 tologic malignancies not in remission before allogeneic hematopoietic stem cell transplantation (HSCT
183 id Services released their Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT
184 mes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT
185 roximately 15,000 to 20,000 patients undergo allogeneic hematopoietic stem cell transplantation (HSCT
186 remains the major barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT
187 ly limits the application and the success of allogeneic hematopoietic stem cell transplantation (HSCT
188 mmune-mediated graft-versus-leukemia effect, allogeneic hematopoietic stem cell transplantation (HSCT
189 microangiopathy (PTMA) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT
190 Human leukocyte antigen (HLA)-mismatched allogeneic hematopoietic stem cell transplantation (HSCT
191 s a similar effect on CMV reactivation after allogeneic hematopoietic stem cell transplantation (HSCT
192 nts with multiple myeloma (MM) who underwent allogeneic hematopoietic stem cell transplantation (HSCT
193 Immunoincompetence after allogeneic hematopoietic stem cell transplantation (HSCT
194 Allogeneic hematopoietic stem cell transplantation (HSCT
195 disease (GVHD) and hematopoietic recovery in allogeneic hematopoietic stem cell transplantation (HSCT
196 Allogeneic hematopoietic stem cell transplantation (HSCT
197 of morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT
198 st disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (HSCT
199 As) are known targets of donor T cells after allogeneic hematopoietic stem cell transplantation (HSCT
200 and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT
201 This report describes the first allogeneic hematopoietic stem cell transplantation (HSCT
202 pstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT
203 solid-organ transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT
204 relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT
205 Allogeneic hematopoietic stem cell transplantation (HSCT
206 nt and maintenance of immune tolerance after allogeneic hematopoietic stem cell transplantation (HSCT
207 viruses may cause severe complications after allogeneic hematopoietic stem cell transplantation (HSCT
208 Despite recent advances in the field of allogeneic hematopoietic stem cell transplantation (HSCT
209 ictive role in the context of autologous and allogeneic hematopoietic stem cell transplantation (HSCT
210 kinesis 8 (DOCK8) deficiency can be cured by allogeneic hematopoietic stem cell transplantation (HSCT
211 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT
212 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT
213 Allogeneic hematopoietic stem cell transplantation (HSCT
214 (cGVHD) remains a major late complication of allogeneic hematopoietic stem cell transplantation (HSCT
215 Allogeneic hematopoietic stem cell transplantation (HSCT
216 Allogeneic hematopoietic stem cell transplantation (HSCT
217 sus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT
218 Allogeneic hematopoietic stem cell transplantation (HSCT
219 mains a significant cause of morbidity after allogeneic hematopoietic stem cell transplantation (HSCT
220 The treatment of CIDs with allogeneic hematopoietic stem cell transplantation (HSCT
221 Allogeneic hematopoietic stem cell transplantation (HSCT
222 In allogeneic hematopoietic stem cell transplantation (HSCT
223 mbotic microangiopathy (TMA) occurring after allogeneic hematopoietic stem cell transplantation (HSCT
224 against tumor recurrence and infection after allogeneic hematopoietic stem cell transplantation (HSCT
225 ns of molecular aberrations on outcome after allogeneic hematopoietic stem cell transplantation (HSCT
226 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT
227 orbidity and mortality in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT
228 ed to be evaluated regarding eligibility for allogeneic hematopoietic stem cell transplantation (HSCT
229 and mediate graft-versus-leukemia following allogeneic hematopoietic stem cell transplantation (HSCT
230 ese types of mutations predict outcome after allogeneic hematopoietic stem-cell transplantation (HSCT
231 mal residual disease (MRD) response, rate of allogeneic hematopoietic stem-cell transplantation (HSCT
232 al residual disease (MRD) can be improved by allogeneic hematopoietic stem-cell transplantation (HSCT
233 the hypothesis that the clinical outcomes of allogeneic hematopoietic stem-cell transplantation (HSCT
234 ease (GVHD) is a major barrier to successful allogeneic hematopoietic stem-cell transplantation (HSCT
235 r this alteration also affects outcome after allogeneic hematopoietic stem-cell transplantation (HSCT
236 Of the cancers treated with allogeneic hematopoietic stem-cell transplantation (HSCT
237 nd efficacy of total skin electron beam with allogeneic hematopoietic stem-cell transplantation (HSCT
238 is of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation (HSCT
239 us-host disease (GVHD) limits the success of allogeneic hematopoietic stem-cell transplantation (HSCT
240 Allogeneic hematopoietic stem-cell transplantation (HSCT
241 gher risk of mortality among Hispanics after allogeneic hematopoietic stem-cell transplantation (HSCT
242 trospective study to evaluate the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT
243 ensity chemotherapy conditioning regimen and allogeneic hematopoietic stem-cell transplantation (HSCT
244 netic basis of MDS influences the outcome of allogeneic hematopoietic stem-cell transplantation (HSCT
245 nor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT
246 ment of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT
247 Allogeneic hematopoietic stem-cell transplantation (HSCT
248 Previous observational studies suggest that allogeneic hematopoietic stem-cell transplantation (HSCT
249 report on durable clinical remissions after allogeneic hematopoietic stem cell transplantation in 2
250 highlights the need for early diagnosis and allogeneic hematopoietic stem cell transplantation in af
252 ive study for reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in ol
254 ally searched for in women who have received allogeneic hematopoietic stem-cell transplantation in an
255 h genital chronic GVHD (cGVHD) who underwent allogeneic hematopoietic stem-cell transplantation in ou
256 Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, incl
257 yeloid leukemia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induc
258 Selection of a suitable graft for allogeneic hematopoietic stem cell transplantation invol
266 ciency related to R in patients who received allogeneic hematopoietic stem-cell transplantation is un
267 (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, litt
268 ted with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more
269 the genome has significant implications for allogeneic hematopoietic stem cell transplantation, not
270 had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or hi
271 ADA coupled to polyethylene glycol or allogeneic hematopoietic stem cell transplantation rapid
272 stress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recip
273 All allogeneic hematopoietic stem cell transplantation recip
274 On the contrary, long-term allogeneic hematopoietic stem cell transplantation recip
275 udies that focused on MSC treatment of adult allogeneic hematopoietic stem cell transplantation recip
276 d minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, rela
277 Allogeneic hematopoietic stem-cell transplantation remai
278 onsidered for reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation (RIC-
280 eplacing myeolablative conditioning prior to allogeneic hematopoietic stem cell transplantation (SCT)
281 hesis that early reconstitution of DCs after allogeneic hematopoietic stem cell transplantation (SCT)
283 Therefore, allogeneic hematopoietic stem cell transplantation shoul
284 ell-mediated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, sugg
285 l membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survi
286 f nonmyeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation that
288 s an important factor for donor selection in allogeneic hematopoietic stem cell transplantation, the
289 Two patients died early in childhood; after allogeneic hematopoietic stem-cell transplantation, the
290 es to increase the number of Tregs following allogeneic hematopoietic stem cell transplantation to pr
293 upper GI tract on 201 patients who underwent allogeneic hematopoietic stem cell transplantation were
294 that achieved long-term remission following allogeneic hematopoietic stem cell transplantation were
295 s despite improved treatment options such as allogeneic hematopoietic stem cell transplantation, whic
296 disease (GvHD) is a major complication after allogeneic hematopoietic stem cell transplantation which
297 Wider application of immunotherapies such as allogeneic hematopoietic stem cell transplantation with
298 vasan et al report that mice conditioned for allogeneic hematopoietic stem cell transplantation with
300 d immune deficiency (SCID) may be treated by allogeneic hematopoietic stem cell transplantation witho
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。